Revitalising cancer trials post-pandemic: time for reform

Cienne Morton*, Richard Sullivan, Debashis Sarker, John Posner, James Spicer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

The COVID-19 pandemic posed significant risk to the health of cancer patients, compromised standard cancer care and interrupted clinical cancer trials, prompting dramatic streamlining of services. From this health crisis has emerged the opportunity to carry forward an unexpected legacy of positive reforms to clinical cancer research, where conventionally convoluted approvals processes, inefficient trial design, procedures and data gathering could benefit from the lessons in rationalisation learned during the pandemic.

Original languageEnglish
Pages (from-to)1409-1414
Number of pages6
JournalBritish journal of cancer
Volume128
Issue number8
DOIs
Publication statusPublished - 12 Apr 2023

Fingerprint

Dive into the research topics of 'Revitalising cancer trials post-pandemic: time for reform'. Together they form a unique fingerprint.

Cite this